C-MER Medical Holdings Limited (C-MER Medical) disclosed a next-day return confirming the on-market repurchase of 220,000 ordinary shares on 14 July 2026. The shares were bought at prices between HKD 0.93 and HKD 0.94, representing a volume-weighted average cost of HKD 0.9303 per share. Total consideration amounted to HKD 0.20 million.

Following the transaction, the company’s outstanding share count (excluding treasury shares) fell 0.0182% to 1.21 billion shares. Treasury stock increased to 22.23 million shares, while the total issued share capital remained unchanged at 1.23 billion shares.

The buyback was conducted under the general mandate granted on 20 May 2026, which authorises the repurchase of up to 123.23 million shares. To date, 0.22 million shares—equivalent to 0.0179% of the issued share base at the mandate date—have been repurchased under this authorisation and are being held as treasury shares.

In line with Hong Kong listing rules, C-MER Medical is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 August 2026.